AstraZeneca, the British-Swedish pharmaceutical giant known for its global footprint in medicine research and development, has reached a major milestone by officially launching its ordinary shares on the New York Stock Exchange (NYSE) for the first time, marking a fresh chapter in its presence on the world’s largest financial stage. This step aligns the company’s…
We are witnessing a defining moment in the global pharmaceutical and stock market landscape. A major agreement has been announced where AstraZeneca will pay up to $18.5 billion to CSPC Pharmaceutical Group to gain access to a new pipeline of obesity drugs. This deal stands among the largest collaborations ever seen in the obesity treatment…
AstraZeneca, the UK’s largest pharmaceutical company, has announced plans to directly list its shares on the New York Stock Exchange (NYSE), transitioning from its current Nasdaq-traded American Depositary Receipts (ADRs). This strategic move aims to broaden global investor access, particularly enabling U.S. pension fund investments, while reaffirming that its headquarters will remain in Cambridge, England,…
AstraZeneca has just made a massive move that could change the face of American pharmaceutical manufacturing. The British drugmaker, known for its innovations in cancer and respiratory treatments, has committed a whopping $50 billion to expand its manufacturing and research operations in the United States by 2030. This announcement was made on July 22, and…
AstraZeneca has just revealed a bold plan to invest $50 billion (£37 billion) in the United States over the next five years, stretching through 2030. This massive commitment, announced on July 21, 2025, aims to strengthen its position in its biggest market while tackling growing concerns about tariffs on drug imports. For anyone watching the…